Christopher Columbus’s DNA to shed light on his origins – BBC News
Research seeking to solve the mystery of the legendary explorer’s birthplace will feature in a documentary.
Related Articles
When to Stay or Leave Your Physician Job – FREE Webinar
At the free, LIVE class, you’ll get everything you need to make your decision & upgrade your job in 2025, regardless if you stay or…
Standing up for general practice
As Iona Heath handed over the Presidency of the Royal College of General Practitioners (RCGP) in 2012, she gave an interview in which she warned…
‘Operating in the Stone Age’: NHS staff’s daily struggle with outdated tech
Plans to digitise health service must first tackle ‘flip a coin’ nature of equipment across UK, say medical staff
The Future of Medical Information
Perhaps we are at an inflection point for the dissemination of medical information
All-in-one gene therapy alternative for DBAS
Diamond-Blackfan anemia syndrome is a ribosomopathy classified among the bone marrow failure syndromes. This disease exhibits significant heterogeneity, with up to 24 genetic variants identified…
Oncotarget’s Editorial Policies | Oncotarget
Learn about submission, peer-review, production, billing, licensing, indexing, and post-publication promotion at Oncotarget
Facing death differently: revolutionising our approach to death and grief
Despite growing public interest in death, support for end-of-life care and bereavement remains inadequate. We urgently need a community centred, public health approach to the…
1691P Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T
CheckMate 67T (NCT04810078) is a multicenter, randomized, open-label, phase 3 trial of NIVO SC vs IV in previously treated pts with advanced/metastatic ccRCC. In the…
Regulated GATA1 expression as a universal gene therapy for Diamond-Blackfan anemia
Gene therapy for Diamond-Blackfan anemia is constrained by dozens of causative mutations. Voit and colleagues develop a universal gene therapy through erythroid-lineage-restricted expression of GATA1…
Primary large B-cell lymphomas of immune-privileged sites
Edited by Associate Editor Michael Hallek and Podcast Editor Laurie H. Sehn, this Review Series highlights the biologic features of, clinical phenotype of,
